PET/MRI在高级别脑胶质瘤放射治疗中的应用

doi:10.11904/j.issn.1002-3070.2017.06.016

摘要/Abstract

摘要： 脑胶质瘤是最常见的原发性神经系统肿瘤,其中高级别胶质瘤生长迅速,常呈浸润性生长,且治疗后易复发,死亡率和致残率都很高。手术切除仍是高级别胶质瘤的首选治疗方法,术后放射治疗则是其重要的辅助治疗手段之一。目前放射治疗多以MRI图像指导靶区的勾画,但MRI在肿瘤显像方面仍存在局限性。随着多种放射性示踪剂的研究及应用,PET能够通过肿瘤组织的代谢变化来反映肿瘤的浸润范围,还有助于鉴别放射性坏死与肿瘤复发。PET/MRI的联合应用在高级别脑胶质瘤的放射治疗中具有很好的应用前景。

关键词: 高级别脑胶质瘤, 正电子发射断层显像术, 磁共振显像, 放射治疗

Abstract: Regulation of calcineurin 1(RCAN1),as an endogenous protein that interacts with calcineurin(CaN),widely expresses in many malignant tumor cells,such as small cell lung cancer,thyroid cancer,leukemia,liver cancer,malignant glioma,endometrial adenocarcinoma and so on.In recent years,many studies have been shown that when RCAN1 is highly expressed,it can inhibit tumor proliferation,differentiation,invasion and metastasis by a variety of ways,thereby inhibiting tumor progression.These findings play an important role in the survival and prognosis of patients,and provide a theoretical basis for the treatment and intervention of malignant tumors.

Key words: High-grade glioma, Positron emission tomography, Magnetic resonance imaging, Radiotherapy

中图分类号:

R739.41

赵永瑞, 徐建堃审校. PET/MRI在高级别脑胶质瘤放射治疗中的应用[J]. 实用肿瘤学杂志, 2017, 31(6): 564-568.

ZHAO Yongrui, XU Jiankun. The application of PET/MRI in high-grade glioma by radiotherapy[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 564-568.

参考文献

1 Louis DN,Ohgaki H,Wiestler OD,et al.The 2007 WHO classification of tumours of the central nervous system[J].Acta Neuropathol,2007,114(2):97-109.
2 Ahmed R,Oborski MJ,Hwang M,et al.Malignant gliomas:current perspectives in diagnosis,treatment,and early response assessment using advanced quantitative imaging methods[J].Cancer Manag Res,2014,6:149-170.
3 Mertens K,Acou M,Van Hauwe J,et al.Validation of ¹⁸F-FDG PET at conventional and delayed intervals for the discrimination of high-grade from low-grade gliomas:a stereotactic PET and MRI study[J].Clin Nucl Med,2013,38(7):495-500.
4 Sweeney R,Polat B,Samnick S,et al.O-(2-[¹⁸F]fluoroethyl)-L-tyrosine uptake is an independent prognostic determinant in patients with glioma referred for radiation therapy[J].Ann Nucl Med,2014,28(2):154-162.
5 Miyake K,Shinomiya A,Okada M,et al.Usefulness of FDG,MET and FLT-PET studies for the management of human gliomas[J].J Biomed Biotechnol,2012,2012:205818.
6 Collet S,Valable S,Constans JM,et al.[¹⁸F]-fluoro-L-thymidine PET and advanced MRI for preoperative grading of gliomas[J].Neuroimage Clin,2015,8:448-454.
7 Schwarzenberg J,Czernin J,Cloughesy TF,et al.3′-deoxy-3′-¹⁸F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab[J].J Nucl Med,2012,53(1):29-36.
8 Bell C,Dowson N,Puttick S,et al.Increasing feasibility and utility of(¹⁸)F-FDOPA PET for the management of glioma[J].Nucl Med Biol,2015,42(10):788-795.
9 Ledezma CJ,Chen W,Sai V,et al.¹⁸F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas:initial experience[J].Eur J Radiol,2009,71(2):242-248.
10 Ullrich RT,Kracht L,Brunn A,et al.Methyl-L-¹¹C-methionine PET as a diagnostic marker for malignant progression in patients with glioma[J].J Nucl Med,2009,50(12):1962-1968.
11 Sharma R,D′Souza M,Jaimini A,et al.A comparison study of ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography-computed tomography scans in evaluation of patients with recurrent brain tumors[J].Indian J Nucl Med,2016,31(2):93-102.
12 Stall B,Zach L,Ning H,et al.Comparison of T2 and FLAIR imaging for target delineation in high grade gliomas[J].Radiat Oncol,2010,5:5-11.
13 Wen PY,Macdonald DR,Reardon DA,et al.Updated response assessment criteria for high-grade gliomas:response assessment in neuro-oncology working group[J].J Clin Oncol,2010,28(11):1963-1972.
14 Cabrera AR,Kirkpatrick JP,Fiveash JB,et al.Radiation therapy for glioblastoma:Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline[J].Pract Radiat Oncol,2016,6(4):217-225.
15 Lucas JJ,Serrano N,Kim H,et al.¹¹C-Methionine positron emission tomography delineates non-contrast enhancing tumor regions at high risk for recurrence in pediatric high-grade glioma[J].J Neurooncol,2017,132(1):163-170.
16 Navarria P,Reggionri G,Pessina F,et al.Investigation on the role of integrated PET/MRI for target volume and radiotherapy planning in patients with high grade glioma[J].Radiother Oncol,2014,112(3):425-429.
17 Grosu AL,Weber WA,Riedel E,et al.L-(methyl-¹¹C)methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy[J].Int J Radiat Oncol Biol Phys,2005,63(1):64-74.
18 闫文明,王宏伟,郁志龙,等.生物靶区定位在胶质瘤术后放射治疗的临床价值研究[J].实用癌症杂志.2016,31(8):1349-1351.
19 Munck ARP,Costa J,Engelholm SA,et al.Impact of[¹⁸F]-fluoro-ethyl-tyrosine PET imaging on target definition for radiation therapy of high-grade glioma[J].Neuro Oncol,2015,17(5):757-763.
20 Piroth MD,Holy R,Pinkawa M,et al.Prognostic impact of postoperative,pre-irradiation ¹⁸F-fluoroethyl-L-tyrosine uptake in glioblastoma patients treated with radiochemotherapy[J].Radiother Oncol,2011,99:218-224.
21 Niyazi M,Geisler J,Siefert A,et al.FET-PET for malignant glioma treatment planning[J].Radiother Oncol,2011,99(1):44-48.
22 Chao ST,Suh JH,Raja S,et al.The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery[J].Int J Cancer,2001,96(3):191-197.
23 Garcia JR,Cozar M,Baquero M,et al.The value of ¹¹C-methionine PET in the early differentiation between tumour recurrence and radionecrosis in patients treated for a high-grade glioma and indeterminate MRI[J].Rev Esp Med Nucl Imagen Mol,2016,2017,36(2):85-90.
24 Shishido H,Kawai N,Miyake K,et al.Diagnostic value of ¹¹C-Methionine(MET)and ¹⁸F-Fluorothymidine(FLT)positron emission tomography in recurrent high-grade gliomas;differentiation from treatment-induced tissue necrosis[J].Cancers,2012,4(1):244-256.
25 Jansen NL,Schwartz C,Graute VA,et al.Prediction of oligodendroglial histology and LOH 1p/19q using dynamic[¹⁸F]FET-PET imaging in intracranial WHO grade II and III gliomas[J].Neuro Oncol,2012,14(12):1473-1480.
26 Niyazi M,Jansen N,Ganswindt U,et al.Re-irradiation in recurrent malignant glioma:prognostic value of [¹⁸F]FET-PET[J].J Neuron Oncol,2012,110(3):389-395.
27 Galldiks N,Rapp M,Stoffels G,et al.Response assessment of bevacizumab in patients with recurrent malignant glioma using [¹⁸F]Fluoroethyl-1-tyrosine PET in comparison to MRI[J].Eur J Nucl Med Mol Imaging,2013,40(1):22-33.
28 Galldiks N,Stoffels G,Ruge MI,et al.Role of O-(2-¹⁸F-Fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma[J].J Nucl Med,2013,54(12):2046-2054.
29 Jena A,Taneja S,Gambhir A,et al.Glioma recurrence versus radiation necrosis:Single-session multiparametric approach using simultaneous O-(2-¹⁸F-Fluoroethyl)-L-tyrosine PET/MRI[J].Clin Nucl Med,2016,41(5):228-236.

[1]	李珊,赵春波,乔文波. 术中放疗在胰腺癌中的应用进展[J]. 实用肿瘤学杂志, 2019, 33(3): 280-283.
[2]	张攀, 张迪综述, 戴晓波审校. 复发鼻咽癌再程放射治疗的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 92-96.
[3]	杜夜生, 胡松柳, 徐向英. 非小细胞肺癌寡转移的立体定向放射治疗研究[J]. 实用肿瘤学杂志, 2018, 32(2): 154-158.
[4]	孙明亮, 徐建宇, 徐向英. 早期非小细胞肺癌立体定向放疗的相关研究[J]. 实用肿瘤学杂志, 2018, 32(1): 53-56.
[5]	刘国慧, 谷安鑫, 殷洪涛, 曹阳, 贺云龙, 王春波, 鄂明艳. 原苏木素A对胃癌SGC-7901细胞系放疗增敏作用的研究[J]. 实用肿瘤学杂志, 2017, 31(6): 500-505.
[6]	罗佳宁, 郝春成, 张建鑫, 卢江岳, 葛晓峰. 术后辅助放疗对三阴性乳腺癌患者预后的影响[J]. 实用肿瘤学杂志, 2017, 31(5): 411-416.
[7]	王赫隆, 云惟康, 王业伟, 冯丽娜, 白彦灵. 三种照射技术在髓母细胞瘤放射治疗中的剂量学分析[J]. 实用肿瘤学杂志, 2017, 31(5): 436-440.
[8]	陈子印, 钱茂森, 潘慧莹. 非共面野在早期非小细胞肺癌立体定向放射治疗方面的剂量学优势[J]. 实用肿瘤学杂志, 2017, 31(2): 142-146.
[9]	曲媛媛，徐向英，庄明，殷洪涛，胡松柳，王春波，曹阳. 尼妥珠单抗对肺癌A549细胞系的体外放射增敏效应[J]. 实用肿瘤学杂志, 2016, 30(6): 497-501.
[10]	吴煜良，何松美，张纯，吴伟艺，崔顺景，赵艳海. 迭代次数在宫颈癌术后调强放疗计划中对子野权重优化的影响[J]. 实用肿瘤学杂志, 2016, 30(6): 507-510.
[11]	刘伟综述, 李惠艳审校. 表皮生长因子受体与放射敏感性关系的研究进展[J]. 实用肿瘤学杂志, 2016, 30(3): 275-278.
[12]	师镘茹综述, 鄂明艳审校. 乳腺癌亚型对放疗反应及潜在放疗敏感性的影响[J]. 实用肿瘤学杂志, 2016, 30(2): 154-157.
[13]	罗红雨, 李嘉琪, 栾瑾微, 张思亮综述, 李香兰审校. 三阴性乳腺癌放射治疗的研究进展[J]. 实用肿瘤学杂志, 2016, 30(2): 180-183.
[14]	刘纤, 任刚, 李莉琴, 朱夫海, 夏廷毅. 胰腺癌螺旋断层调强放疗高剂量少分次模式的胃肠毒副反应相关因素分析[J]. 实用肿瘤学杂志, 2015, 29(6): 481-486.
[15]	李剑, 徐向英, 胡松柳. 原发性气管肿瘤治疗的研究进展[J]. 实用肿瘤学杂志, 2015, 29(6): 557-560.